X4 Pharmaceuticals (XFOR) AI Stock Analysis

• Market Cap: $24.89M
• Dividend Yield: N/A
• Average Volume (3M): 204.89K
• Price to Earnings (P/E): 1.8
• Beta (1Y): 1.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.04
• Shares Outstanding: 5,788,745
• 10 Day Avg. Volume: 182,766
• 30 Day Avg. Volume: 204,886
• PEG Ratio: <0.01
• Price to Book (P/B): 0.97
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $57.75
• Price Target Upside: 1522.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 44 Neutral
• Price Target: ―

X4 Pharmaceuticals faces significant financial challenges, notably in profitability and cash flow, despite growth in revenue. Technical indicators suggest a downward trend, while valuation metrics indicate potential undervaluation. The earnings call and recent corporate events offer some optimism with strategic initiatives and clinical progress, but market and sales challenges remain.

Positive Factors

Financial Performance

The company reported total revenue of $28.8M, compared to the consensus estimate of $11.6M, and a net income of $0.04 per share, compared to the consensus estimated a net loss of $0.12 per share.

Licensing Agreement

X4 Pharmaceuticals has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of mavorixafor in Europe, Australia, and New Zealand.

Product Revenue Growth

XOLREMDI sales increased significantly, surpassing estimates, due to commercialization progress and inventory build.

Negative Factors

Commercialization Challenges

The longer-than-expected time to diagnose and initiate therapy for new WHIM patients and the high commercial cost to onboard a patient are challenges faced by the company.

Financing Needs

Despite the collaboration, additional capital is still considered necessary to provide sufficient runway to topline data from the P3 4WARD trial.

Market Adoption

Market adoption of the drug has not been as robust as expected.

X4 Pharmaceuticals Business Overview & Revenue Model

Company Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

X4 Pharmaceuticals generates revenue primarily through the development and commercialization of its pipeline of drug candidates. The company aims to bring its lead product, mavorixafor, to market, which is expected to be a key revenue driver upon approval. Revenue is also derived from strategic collaborations and partnerships with other pharmaceutical companies, which may include milestone payments, research funding, and royalties. Additionally, X4 may earn revenue through licensing agreements for its proprietary technologies and therapies. The company's focus on rare diseases often allows for orphan drug designations, which can provide market exclusivity and potential pricing power in niche markets.

X4 Pharmaceuticals Financial Statement Overview

Summary

X4 Pharmaceuticals is showing revenue growth but struggles with profitability and cash flow management. Despite leverage improvements, financial stability concerns persist due to low equity levels and high operational costs.

Income Statement

X4 Pharmaceuticals shows a significant increase in total revenue in TTM (Trailing-Twelve-Months) compared to the previous year, indicating growth in their operations. However, the company has consistently reported negative EBIT and EBITDA figures, reflecting operational inefficiencies. The net profit margin is positive in the TTM period, but historical net losses suggest profitability challenges.

Balance Sheet

The company's debt-to-equity ratio has improved in the TTM period due to reduced total debt, indicating better leverage management. However, the equity ratio remains low, suggesting a higher reliance on liabilities to finance assets. The return on equity is positive in the TTM, but the low stockholders' equity raises concerns about financial stability.

Cash Flow

Operating cash flow has been consistently negative, with a significant cash outflow in the TTM period, indicating cash management issues. Free cash flow remains negative, but the company has managed to generate cash through financing activities. The operating cash flow to net income ratio reflects a disconnect between cash flow generation and reported earnings.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
31.36M	2.56M	0.00	0.00	0.00	3.00M
	Gross Profit
25.85M	1.76M	-2.00M	-1.99M	-1.89M	3.00M
	EBIT
-8.55M	-36.40M	-107.52M	-87.57M	-85.11M	-59.87M
	EBITDA
-101.70M	-27.58M	-107.10M	-87.57M	-85.11M	-58.06M
	Net Income Common Stockholders
14.60M	-37.45M	-101.17M	-93.87M	-88.70M	-62.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
76.79M	102.06M	114.22M	121.72M	81.79M	78.71M
	Total Assets
81.25M	146.45M	147.26M	155.59M	117.18M	122.87M
	Total Debt
12.24M	78.09M	58.28M	38.42M	39.78M	38.45M
	Net Debt
-64.56M	22.39M	-40.94M	-83.30M	-42.00M	-40.26M
	Total Liabilities
22.55M	124.30M	96.16M	81.53M	52.76M	50.07M
	Stockholders Equity
58.71M	22.15M	51.10M	74.05M	64.41M	72.80M
Cash Flow		Free Cash Flow
-112.94M	-131.23M	-96.57M	-77.20M	-71.52M	-60.18M
	Operating Cash Flow
-109.67M	-130.90M	-96.51M	-77.10M	-70.91M	-58.82M
	Investing Cash Flow
69.17M	66.99M	-14.88M	-103.00K	-615.00K	-1.36M
	Financing Cash Flow
20.29M	20.29M	88.52M	117.23M	74.25M	12.39M

X4 Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XFOR, the sentiment is Negative. The current price of 3.56 is above the 20-day moving average (MA) of 3.41, below the 50-day MA of 4.57, and below the 200-day MA of 13.14, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 44.45 is Neutral, neither overbought nor oversold. The STOCH value of 65.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XFOR.

X4 Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XLO	54 Neutral	$36.25M	―	-297.84%	―	―	53.92%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
RPTX	53 Neutral	$63.05M	―	-71.64%	―	-98.90%	-177.17%
NRXP	45 Neutral	$56.54M	―	108.28%	―	―	41.01%
XFOR	44 Neutral	$24.89M	1.84	121.75%	―	―	―
PEPG	40 Underperform	$49.08M	―	-75.45%	―	―	14.06%
KPTI	38 Underperform	$38.79M	―	41.08%	―	1.19%	61.65%

X4 Pharmaceuticals Corporate Events

X4 Pharmaceuticals Reports Q1 2025 Financial Results

On May 1, 2025, X4 Pharmaceuticals reported its financial results for the first quarter of 2025, highlighting significant progress in its clinical trials and commercialization efforts. The company is advancing its Phase 3 4WARD trial for chronic neutropenia and has seen a positive response to its drug XOLREMDI in the U.S. market. Strategic restructuring and international partnerships aim to maximize the potential of mavorixafor, while a recent reverse stock split and improved financial performance position the company for future growth.

Spark’s Take on XFOR Stock

According to Spark, TipRanks’ AI Analyst, XFOR is a Neutral.

X4 Pharmaceuticals’ overall stock score reflects significant challenges in financial performance, as indicated by consistent losses and weak cash flow. Technical indicators suggest downward momentum, and valuation metrics are unfavorable with a negative P/E ratio. While the earnings call presented some positive developments, the net losses and market penetration issues remain major concerns. The strategic restructuring is a step towards cost efficiency but adds uncertainty to the company’s future performance.

To see Spark’s full report on XFOR stock, click here.

X4 Pharmaceuticals Announces Strategic Restructuring Plans

X4 Pharmaceuticals announced a strategic restructuring on February 6, 2025, involving a workforce reduction of approximately 30%, the closure of its Vienna facility, and a focus on advancing mavorixafor for chronic neutropenia. This restructuring aims to decrease annual spending by $30-35 million and extend the company’s cash runway into the first half of 2026, by streamlining operations to enhance the global market opportunity for mavorixafor.